RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to shrink Hard-to-Treat lung tumors
Disease control Not yet recruitingThis study tests two drugs—sacituzumab govitecan and ivonescimab—alone or together in people with advanced non-small cell lung cancer that has certain gene changes (like EGFR or ALK) and has come back after prior treatment. The goal is to see if the combination works better than …
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug duo aims to reboot immune system against tough lung cancers
Disease control Not yet recruitingThis study is testing whether a new drug, SX-682, combined with an existing immunotherapy drug (atezolizumab), can help control advanced non-small cell lung cancer that has worsened after standard chemotherapy and immunotherapy. It aims to see if this combination can help the pat…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC